InControl Imaging Raises Seed Funding to Expand Advanced Brain and Spine Diagnostic Services
InControl Imaging, a Moore, Oklahoma-based advanced brain and spine imaging and diagnostics company, has begun its journey into the capital markets with early seed financing aimed at supporting its strategic growth and expansion of its clinical imaging services. Founded in 2025, the company combines state-of-the-art brain and spine imaging technologies with personalized neuroperformance and recovery programs designed to improve patient outcomes, enhance diagnosis accuracy and help individuals recover from neurological and musculoskeletal injuries that might otherwise go undetected or misdiagnosed.
According to public filings, InControl Imaging Investors Moore, LLC conducted a seed equity offering in late 2025 that shows $300,000 raised as part of its initial capital-raising efforts. While the offering remains ongoing, with additional unfilled investment available, the early participation underscores investor interest in the company’s mission to expand access to advanced motion and functional imaging across the U.S.
This seed capital is expected to support InControl Imaging’s rollout of new diagnostic centers and broaden its service footprint beyond its initial Moore location, as well as enhance the clinical capabilities of its VMA® dynamic motion imaging system and other objective testing modalities. Those technologies include real-time spinal motion analysis and advanced EEG-based cognitive assessments that provide deeper insights into neurological function than conventional static MRI and X-ray imaging.
The company’s seed funding round has attracted early backing from a small group of investors, including angel participants and strategic partners aligned with healthcare innovation, although specific institutional names beyond the disclosed investing entity have not been publicly detailed. These investors have provided the upfront capital necessary for InControl Imaging to hire staff, scale operations and invest in medical equipment and facilities capable of delivering its diagnostic programs.
Leadership at InControl Imaging has emphasized that this early capital will allow the company to capitalize on increasing demand for more precise and functional imaging solutions, particularly in contexts such as concussion assessment, post-injury evaluation and complex spine dysfunction. By delivering non-invasive, objective tests with rapid turnaround times, the company seeks to fill what it describes as a critical gap in clinical practice, where many injuries are often under-diagnosed or misunderstood using traditional imaging methods.
The seed fundraising also sets the stage for potential future capital raises that could include venture capital participation or broader private placement offerings as the company continues to expand its network of diagnostic centers. In its investor communications, InControl Imaging highlights a scalable operating model and long-term growth opportunity within the diagnostic and functional imaging market, which continues to gain attention as providers seek more actionable and performance-based clinical data.
Industry observers have noted that imaging companies integrating advanced diagnostics with recovery and performance programs are well positioned as healthcare shifts toward precision medicine and value-based care. Securing early funding through a seed round allows InControl Imaging to establish its operational foundation while preparing for potential later-stage investors interested in supporting innovation in neurodiagnostics and musculoskeletal assessment.
InControl Imaging’s leadership team has underscored the importance of combining clinical expertise with sustained technology investment to remain at the forefront of diagnostic imaging advancements. The capital raised in the seed offering is expected to play a key role in recruiting clinical and technical talent, expanding testing modalities and forming partnerships with referring physicians and healthcare providers.
As the company moves from its seed stage into its next phase of growth, InControl Imaging is expected to continue engaging investors aligned with its focus on improving diagnostic accuracy and patient outcomes through advanced imaging technologies. With early financial backing and a clearly defined clinical mission, the company is positioning itself to expand its presence in the healthcare diagnostics landscape and drive broader adoption of imaging approaches that go beyond conventional methods.
